Following the Company’s announcement last week confirming the first sales of Striate+ in Canada, Orthocell’s Chairman John Van Der Wielen spoke with Proactive’s Tylah Tully about the Company’s swift transition from regulatory approval to sales in the Canadian market, and plans to expand into the Singapore and Brazil markets within the next six to 12 months.
Take a look: